
A promising new drug called rusfertide is sparking hope in the treatment of polycythemia vera, a rare blood cancer. In a recent clinical trial involving 70 patients, rusfertide effectively reduced excess red blood cell production, leading to a decreased need for phlebotomy and an overall improvement in quality of life for those affected. Conducted by researchers from the Icahn School of Medicine at Mount Sinai, the trial revealed positive outcomes in terms of safety and the long-term control of hematocrit levels.
Rusfertide, acting as a mimic of the hormone hepcidin, presents a potential breakthrough in the management of polycythemia vera. T......
Read Full article on GretAi
Comments
Post a Comment